A fresh look at tumor immunosurveillance and immunotherapy (original) (raw)

• Coley, W. B. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci. 105, 487–511 (1893).
  Article Google Scholar
• Burnet, F. M. Cancer: a biological approach. Br. Med. J. 1, 779–786 (1957).
  Article CAS PubMed PubMed Central Google Scholar
• Burnet, F. M. Immunological aspects of malignant disease. Lancet 1, 1171–1174 (1967).
  Article CAS PubMed Google Scholar
• Ada, G. The coming of age of tumour immunotherapy. Immunol. Cell Biol. 77, 180–185 (1999).
  Article CAS PubMed Google Scholar
• Stutman, O. Immunodepression and malignancy. Adv. Cancer Res. 22, 261–422 (1975).
  Article CAS PubMed Google Scholar
• Medzhitov, R. & Janeway, C. Jr Innate immune recognition: mechanisms and pathways. Immunol. Rev. 173, 89–97 (2000).
  Article CAS PubMed Google Scholar
• Fuchs, E. J. & Matzinger, P. Is cancer dangerous to the immune system? Semin. Immunol. 8, 271–280 (1996).
  Article CAS PubMed Google Scholar
• Gallucci, S., Lolkema, M. & Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nature Med. 5, 1249–1255 (1999).
  Article CAS PubMed Google Scholar
• Gallucci, S. & Matzinger, P. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 13, 114–119 (2001).
  Article CAS PubMed Google Scholar
• Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991–1045 (1994).
  Article CAS PubMed Google Scholar
• Bennett, S. R. et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478–480 (1998).
  Article CAS PubMed Google Scholar
• Ridge, J. P., Fuchs, E. J. & Matzinger, P. Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science 271, 1723–1726 (1996).
  Article CAS PubMed Google Scholar
• Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R. & Melief, C. J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480–483 (1998).
  Article CAS PubMed Google Scholar
• Rosenberg, S. A. et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4, 321–327 (1998).
  Article CAS PubMed Google Scholar
• Marchand, M. et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer 63, 883–885 (1995).
  Article CAS PubMed Google Scholar
• Jager, E., Jager, D. & Knuth, A. CTL-defined cancer vaccines: perspectives for active immunotherapeutic interventions in minimal residual disease. Cancer Metastasis Rev. 18, 143–150 (1999).
  Article CAS PubMed Google Scholar
• Van den Eynde, B. J. & van der Bruggen, P. T cell defined tumor antigens. Curr. Opin. Immunol. 9, 684–693 (1997).
  Article CAS PubMed Google Scholar
• Wang, R. F. & Rosenberg, S. A. Human tumor antigens for cancer vaccine development. Immunol. Rev. 170, 85–100 (1999).
  Article CAS PubMed Google Scholar
• Houghton, A. N. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180, 1–4. (1994).
  Article CAS PubMed Google Scholar
• Wolfel, T. et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281–1284 (1995).
  Article CAS PubMed Google Scholar
• Rickinson, A. B. & Moss, D. J. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 15, 405–431 (1997).
  Article CAS PubMed Google Scholar
• Pfreundschuh, M. Exploitation of the B cell repertoire for the identification of human tumor antigens. Cancer Chemother. Pharmacol. 46, 3–7 (2000).
  Article Google Scholar
• Robert, J. & Cohen, N. Evolution of immune surveillance and tumor immunity: studies in Xenopus. Immunol. Rev. 166, 231–243 (1998).
  Article CAS PubMed Google Scholar
• Groh, V. et al. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl Acad. Sci. USA 93, 12445–12450 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Groh, V., Steinle, A., Bauer, S. & Spies, T. Recognition of stress-induced MHC molecules by intestinal epithelial γδ T cells. Science 279, 1737–1740 (1998).
  Article CAS PubMed Google Scholar
• Diefenbach, A., Jamieson, A. M., Liu, S. D., Shastri N. & Raulet, D. H. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nature Immunol. 1, 119–126 (2000).
  Article CAS Google Scholar
• Cerwenka, A. et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12, 721–727 (2000).
  Article CAS PubMed Google Scholar
• Bauer, S. et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727–729 (1999).
  Article CAS PubMed Google Scholar
• Whiteside, T. L. & Herberman, R. B. The role of natural killer cells in immune surveillance of cancer. Curr. Opin. Immunol. 7, 704–710 (1995).
  Article CAS PubMed Google Scholar
• Godfrey, D. I., Hammond, K. J., Poulton, L. D., Smyth, M. J. & Baxter, A. G. NKT cells: facts, functions and fallacies. Immunol. Today 21, 573–583 (2000).
  Article CAS PubMed Google Scholar
• Smyth, M. J. & Godfrey, D. I. NKT cells and tumor immunity: a double edged sword. Nature Immunol. 1, 459–460 (2000).
  Article CAS Google Scholar
• Lanier, L. L. NK cell receptors. Annu. Rev. Immunol. 16, 359–393 (1998).
  Article CAS PubMed Google Scholar
• Salcedo, M. Inhibitory role of murine Ly49 lectin-like receptors on natural killer cells. Curr. Top. Microbiol. Immunol. 244, 97–105 (1999).
  CAS PubMed Google Scholar
• Takei, F., Brennan, J. & Mager, D. L. The Ly 49 family: genes, proteins and recognition of class I MHC. Immunol. Rev. 155, 67–77 (1997).
  Article CAS PubMed Google Scholar
• Lopez-Botet, M., Llano, M., Navarro, F. & Bellon, T. NK cell recognition of non-classical HLA class I molecules. Semin. Immunol. 12, 109–119 (2000).
  Article CAS PubMed Google Scholar
• Braud, V. M. & McMichael, A. J. Regulation of NK cell functions through interaction of the CD94/NKG2 receptors with the nonclassical class I molecule HLA-E. Curr. Top. Microbiol. Immunol. 244, 85–95 (1999).
  CAS PubMed Google Scholar
• Park, S. H. & Bendelac, A. CD1-restricted T-cell responses and microbial infection. Nature 406, 788–792 (2000).
  Article CAS PubMed Google Scholar
• Moretta, A., Biassoni, R., Bottino, C., Mingari, M. C. & Moretta, L. Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol. Today 21, 228–234 (2000).
  Article CAS PubMed Google Scholar
• Wu, J. et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285, 730–732 (1999).
  Article CAS PubMed Google Scholar
• Cosman, D. et al. ULBPs, novel MHC class I–related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14, 123–133 (2001).
  Article CAS PubMed Google Scholar
• Groh, V. et al. Broad tumor-associated expression and recognition by tumor-derived γ δ T cells of MICA and MICB. Proc. Natl Acad. Sci. USA 96, 6879–6884 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Nomura, M. et al. Genomic structures and characterization of Rae1 family members encoding GPI-anchored cell surface proteins and expressed predominantly in embryonic mouse brain. J. Biochem. (Tokyo) 120, 987–995 (1996).
  Article CAS Google Scholar
• Gatti, R. A. & Good, R. A. Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer 28, 89–98 (1971).
  Article CAS PubMed Google Scholar
• McClain, K. L. Immunodeficiency states and related malignancies. Cancer Treat. Res. 92, 39–61 (1997).
  Article CAS PubMed Google Scholar
• Cannon, M. & Cesarman, E. Kaposi's sarcoma-associated herpes virus and acquired immunodeficiency syndrome-related malignancy. Semin. Oncol. 27, 409–419 (2000).
  CAS PubMed Google Scholar
• Paller, A. S. Immunodeficiency syndromes. X-linked aγglobulinemia, common variable immunodeficiency, Chediak-Higashi syndrome, Wiskott-Aldrich syndrome, and X-linked lymphoproliferative disorder. Dermatol. Clin. 13, 65–71 (1995).
  Article CAS PubMed Google Scholar
• Otley, C. C. & Pittelkow, M. R. Skin cancer in _Liver Transpl._ant recipients. Liver Transpl. 6, 253–262 (2000).
  Article CAS PubMed Google Scholar
• Aguilar, L. K., Rooney, C. M. & Heslop, H. E. Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. Curr. Opin. Oncol. 11, 96–101 (1999).
  Article CAS PubMed Google Scholar
• Haliotis, T., Ball, J. K., Dexter, D. & Roder, J. C. Spontaneous and induced primary oncogenesis in natural killer (NK)-cell-deficient beige mutant mice. Int. J. Cancer 35, 505–513 (1985).
  Article CAS PubMed Google Scholar
• Gershwin, M. E., Ohsugi, Y., Castles, J. J., Ikeda, R. M. & Ruebner, B. Anti-mu induces lymphoma in germfree congenitally athymic (nude) but not in heterozygous (nu/+) mice. J. Immunol. 131, 2069–2073 (1983).
  CAS PubMed Google Scholar
• Shultz, L. D. et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J. Immunol. 154, 180–191 (1995).
  CAS PubMed Google Scholar
• Dighe, A. S., Richards, E., Old, L. J. & Schreiber, R. D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN γ receptors. Immunity 1, 447–456. (1994).
  Article CAS PubMed Google Scholar
• Kaplan, D. H. et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl Acad. Sci. USA 95, 7556–7561 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Van den Broek, M. F. et al. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184, 1781–1790 (1996).
  Article CAS PubMed Google Scholar
• Street, S. E., Cretney, E. & Smyth, M. J. Perforin and interferon-γ activities independently control tumor initiation, growth, and metastasis. Blood 97, 192–197 (2001).
  Article CAS PubMed Google Scholar
• Smyth, M. J., Crowe, N. Y., & Godfrey, D. I. NK cells and NKT cells collaborate in host protection from MCA-induced fibrosarcoma. Int. Immunol. 13 (in the press, 2001).
• Smyth, M. J. et al. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 192, 755–760 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Smyth, M. J. et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191, 661–668 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Shustov, A. et al. Role of perforin in controlling B-cell hyperactivity and humoral autoimmunity. J. Clin. Invest. 106, R39–47 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Matloubian, M. et al. A role for perforin in downregulating T-cell responses during chronic viral infection. J. Virol. 73, 2527–2536 (1999).
  CAS PubMed PubMed Central Google Scholar
• Badovinac, V. P., Tvinnereim, A. R. & Harty, J. T. Regulation of antigen-specific CD8(+) T cell homeostasis by perforin and interferon-γ. Science 290, 1354–1358 (2000).
  Article CAS PubMed Google Scholar
• Davidson, W. F., Giese, T. & Fredrickson, T. N. Spontaneous development of plasmacytoid tumors in mice with defective fas-fas ligand interactions. J. Exp. Med. 187, 1825–1838 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Shaukaran, V. et al. IFN-γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001).
• Strander, H. & Einhorn, S. Interferons and the tumor cell. Biotherapy 8, 213–218 (1996).
  Article CAS PubMed Google Scholar
• Rossi, D. & Zlotnik, A. The biology of chemokines and their receptors. Annu. Rev. Immunol. 18, 217–242 (2000).
  Article CAS PubMed Google Scholar
• Ferrone, S. & Marincola, F. M. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today 16, 487–494 (1995).
  Article CAS PubMed Google Scholar
• Elgert, K. D., Alleva, D. G. & Mullins, D. W. Tumor-induced immune dysfunction: the macrophage connection. J. Leukoc. Biol. 64, 275–290 (1998).
  Article CAS PubMed Google Scholar
• Walker, P. R., Saas, P. & Dietrich, P. Y. Tumor expression of Fas ligand (CD95L) and the consequences. Curr. Opin. Immunol. 10, 564–572 (1998).
  Article CAS PubMed Google Scholar
• Harding, C., Heuser, J. & Stahl, P. Endocytosis and intracellular processing of transferrin and colloidal gold-transferrin in rat reticulocytes: demonstration of a pathway for receptor shedding. Eur. J. Cell Biol. 35, 256–263 (1984).
  CAS PubMed Google Scholar
• Kurts, C. et al. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J. Exp. Med. 184, 923–930 (1996).
  Article CAS PubMed Google Scholar
• Davis, I. D. An overview of cancer immunotherapy. Immunol. Cell Biol. 78, 179–195 (2000).
  Article CAS PubMed Google Scholar
• Tamura, Y., Peng, P., Liu, K., Daou, M. & Srivastava, P. K. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278, 117–120 (1997).
  Article CAS PubMed Google Scholar
• Melcher, A. et al. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nature Med. 4, 581–587 (1998).
  Article CAS PubMed Google Scholar
• Chiodoni, C. et al. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J. Exp. Med. 190, 125–133 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Albert, M. L., Sauter, B. & Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86–89 (1998).
  Article CAS PubMed Google Scholar
• Greten, T. F. & Jaffee, E. M. Cancer vaccines. J. Clin. Oncol. 17, 1047–1060 (1999).
  Article CAS PubMed Google Scholar
• Blachere, N. E. et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J. Exp. Med. 186, 1315–1322 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Sakaguchi, S. Animal models of autoimmunity and their relevance to human diseases. Curr. Opin. Immunol. 12, 684–690. (2000).
  Article CAS PubMed Google Scholar
• Sakaguchi, S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101, 455–458 (2000).
  Article CAS PubMed Google Scholar
• Hanninen, A. & Harrison, L. C. γδ T cells as mediators of mucosal tolerance: the autoimmune diabetes model. Immunol. Rev. 173, 109–119 (2000).
  Article CAS PubMed Google Scholar
• Hammond, K. J. L. et al. α/β-T cell receptor (TCR)+CD4−CD8− (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J. Exp. Med. 187, 1047–1056 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Terabe, M. et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nature Immunol. 1, 515–520 (2000).
  Article CAS Google Scholar
• Shimizu, J., Yamazaki, S. & Sakaguchi, S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163, 5211–5218 (1999).
  CAS PubMed Google Scholar
• Onizuka, S. et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 59, 3128–3133 (1999).
  CAS PubMed Google Scholar
• Seo, N., Tokura, Y., Takigawa, M. & Egawa, K. Depletion of IL-10- and TGF-β-producing regulatory γδ T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells. J. Immunol. 163, 242–249 (1999).
  CAS PubMed Google Scholar